All In Biotech

Drug Trial Radar · NCT07742852

ASKC200 for Knee Osteoarthritis Pain

A Multicenter, Randomized, Double-Blind, Active Drug/Placebo-Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of ASKC200 in Patients With Knee Osteoarthritis Pain

Last checked: Nov 20, 2026Latest source record: Aug 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 175 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

175

Actual

Start

Sep 12, 2025

Primary completion

Apr 28, 2026

Study completion Sep 30, 2026

Sponsor

Sponsor type
Industry
First posted
Aug 3, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 40 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase II clinical trial designed to evaluate the efficacy and safety of ASKC200 Lotion in patients with knee osteoarthritis (KOA) pain. A total of 175 eligible patients will be randomly assigned to three groups at a 1:2:2:2 ratio: the experimental group1 (treated with 1% ASKC200 Lotion), the experimental group 2(treated with 5% ASKC200 Lotion), the active control group (treated with Diclofenac Diethylamine Emulgel), and the placebo group (treated with matching placebos).

Conditions

  • Osteoarthritis (OA) of the Knee
  • Pain

Interventions

  • 5% ASKC200Drug

    A single dose will be topically applied to study knees for 60 minutes on Visit 1 on Day 1, Day 2, Day 3, and Day 4.

  • 1% Diclofenac Diethylamine EmulgelDrug

    Day 5-18;Four times daily

  • PlaceboDrug

    ASKC200 Placebo or Diclofenac Diethylamine Placebo

  • 1% ASKC200Drug

    A single dose will be topically applied to study knees for 60 minutes on Visit 1 on Day 1, Day 2, Day 3, and Day 4.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in WAADPI (NRS) of the target knee from baselineTime frame: Day 34

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Hospital

    Beijing, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.